Skip to content
10-Q

Quarterly Report

IOVANCE BIOTHERAPEUTICS, INC. IOVA

0001104659-26-056778

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 15, 2026 446.5M sh
Shares Diluted Q1 2026 · Mar 31, 2026 418.51K sh
Shares Diluted Q1 2026 · Mar 31, 2025 322.87K sh
Capex Q1 2026 · Mar 31, 2026 $6.61M
Capex Q1 2026 · Mar 31, 2025 $6.21M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$72.07M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$103.69M
Short Term Investments Q1 2026 · Mar 31, 2026 $116.94M
Short Term Investments Q1 2026 · Dec 31, 2025 $133.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $196.51M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $163.08M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $171.67M
Stockholders Equity Q1 2026 · Mar 31, 2026 $721.75M
Stockholders Equity Q1 2026 · Dec 31, 2025 $698.58M
Stockholders Equity Q1 2026 · Mar 31, 2025 $767.87M
Stockholders Equity Q1 2026 · Dec 31, 2024 $710.41M
Current Liabilities Q1 2026 · Mar 31, 2026 $129.42M
Current Liabilities Q1 2026 · Dec 31, 2025 $138.36M
Total Liabilities Q1 2026 · Mar 31, 2026 $203.91M
Total Liabilities Q1 2026 · Dec 31, 2025 $214.59M
Current Assets Q1 2026 · Mar 31, 2026 $466.5M
Current Assets Q1 2026 · Dec 31, 2025 $442.69M
Total Assets Q1 2026 · Mar 31, 2026 $925.67M
Total Assets Q1 2026 · Dec 31, 2025 $913.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.19
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.36
Eps Basic Q1 2026 · Mar 31, 2026 −$0.19
Eps Basic Q1 2026 · Mar 31, 2025 −$0.36
Sga Expense Q1 2026 · Mar 31, 2026 $38.95M
Sga Expense restated Q1 2026 · Mar 31, 2025 $43.8M
Rd Expense Q1 2026 · Mar 31, 2026 $62.49M
Rd Expense restated Q1 2026 · Mar 31, 2025 $75.97M
Net Income Q1 2026 · Mar 31, 2026 −$79.05M
Net Income Q1 2026 · Mar 31, 2025 −$116.16M
Operating Income Q1 2026 · Mar 31, 2026 −$81.04M
Operating Income Q1 2026 · Mar 31, 2025 −$121.22M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $42.5M
Cost Of Revenue restated Q1 2026 · Mar 31, 2025 $42.72M
Revenue Q1 2026 · Mar 31, 2026 $71.43M
Revenue Q1 2026 · Mar 31, 2025 $49.32M